NewAmsterdam Pharma Company N.V. Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
NewAmsterdam Pharma Company N.V. (NAMS) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -EUR 49.67 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-07.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2024-10-28
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 6 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|---|
| 2023-06-30 | -49.67M EUR 6-K · filed 2023-08-07 | |
| 2022-12-31 | 383.86M EUR 20-F/A · filed 2024-10-28 | |
| 2022-06-30 | 35.00M EUR 6-K · filed 2023-08-07 | |
| 2021-12-31 | 43.81M EUR 20-F/A · filed 2024-10-28 | |
| 2020-12-31 | 5.34M EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |